← All Chain Bridge I filings

Chain Bridge I Form 4 insider transactions

Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.

OTC.Pink
CBGGF
Chain Bridge I
425: Chain Bridge I Terminates Business Combination Agreement with Phytanix Bio, Changes Accounting Firm
Chain Bridge I terminated its business combination agreement with Phytanix Bio and changed its independent registered public accounting firm from Frank, Rimerman & Co. LLP to RBSM, LLP.
OTC.Pink
CBGGF
Chain Bridge I
425: Phytanix Bio Unveils Investor Deck, Highlights Cannabinoid-Based Therapeutics and Merger with Chain Bridge I
Phytanix Bio, a preclinical pharmaceutical company focused on cannabinoid-based medicines, released its investor deck detailing its strategic vision and growth potential, coinciding with its planned merger with Chain Bridge I.
OTC.Pink
CBGGF
Chain Bridge I
425: Chain Bridge I Announces Business Combination with Phytanix Bio, Targeting Cannabinoid-Based Pharmaceuticals
Chain Bridge I (CBRG) unveils a business combination agreement with Phytanix Bio to develop cannabinoid-based pharmaceuticals, focusing on bladder pain syndrome and treatment-resistant focal seizures.
OTC.Pink
CBGGF
Chain Bridge I
425: Chain Bridge I to Merge with Phytanix Bio, Creating Publicly Traded Cannabinoid Therapeutics Company
Chain Bridge I (CBRG) will merge with Phytanix Bio, a pharmaceutical company focused on cannabinoid-based medicines, with the combined entity expected to trade on Nasdaq under the ticker PHYX.